Jorgen Kokke Sells 19,967 Shares of Genus plc (LON:GNS) Stock

Genus plc (LON:GNSGet Free Report) insider Jorgen Kokke sold 19,967 shares of the business’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of GBX 1,731 ($21.82), for a total transaction of £345,628.77 ($435,629.91).

Genus Price Performance

Shares of LON GNS traded up GBX 76.16 ($0.96) during mid-day trading on Friday, reaching GBX 1,826.16 ($23.02). The company had a trading volume of 461,922 shares, compared to its average volume of 133,295. The firm has a market cap of £1.20 billion, a price-to-earnings ratio of 151.37, a PEG ratio of 2.87 and a beta of 0.37. The business’s 50-day simple moving average is GBX 1,703.05 and its 200 day simple moving average is GBX 1,797.43. Genus plc has a one year low of GBX 1,424 ($17.95) and a one year high of GBX 2,155 ($27.16). The company has a debt-to-equity ratio of 53.12, a quick ratio of 1.08 and a current ratio of 1.80.

Genus (LON:GNSGet Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported GBX 39.80 ($0.50) earnings per share (EPS) for the quarter. Genus had a net margin of 1.18% and a return on equity of 1.41%. On average, research analysts predict that Genus plc will post 70.9644323 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Shore Capital reiterated a “buy” rating on shares of Genus in a research note on Wednesday, December 11th.

Get Our Latest Stock Analysis on GNS

About Genus

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

See Also

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.